The FDA has approved Awiqli, the first once‑weekly long‑acting basal insulin, for adults with type 2 diabetes, which offers ...
Add Yahoo as a preferred source to see more of our stories on Google. The clinical trials assessed once-weekly Awiqli with mealtime insulin Novo Nordisk has secured the US Food and Drug Administration ...
Novo Nordisk has secured the US Food and Drug Administration (FDA) approval for Awiqli (insulin icodec-abae) injection 700 units/mL, a basal insulin for adults with type 2 diabetes (T2D). It is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results